200 related articles for article (PubMed ID: 33414400)
41. Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients.
Miles B; Mackey JD
Cureus; 2021 Jul; 13(7):e16372. PubMed ID: 34422458
[TBL] [Abstract][Full Text] [Related]
42. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH
Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218
[TBL] [Abstract][Full Text] [Related]
43. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
44. Autologous transplant and second malignancies in MM.
Pasvolsky O; Bashir Q
Blood Adv; 2023 Jun; 7(12):2731-2732. PubMed ID: 37318936
[No Abstract] [Full Text] [Related]
45. Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention.
Okada N; Hanafusa T; Abe S; Sato C; Nakamura T; Teraoka K; Abe M; Kawazoe K; Ishizawa K
Support Care Cancer; 2016 Sep; 24(9):3979-85. PubMed ID: 27129837
[TBL] [Abstract][Full Text] [Related]
46. [Secondary solid tumors in autologous-peripheral blood stem cell transplantation recipients].
Fujii H; Ueda Y; Nakagawa H
Rinsho Ketsueki; 2000 Aug; 41(8):621-7. PubMed ID: 11020988
[TBL] [Abstract][Full Text] [Related]
47. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
48. The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation.
Kopinska A; Krawczyk-Kulis M; Dziaczkowska-Suszek J; Bieszczad K; Jagoda K; Kyrcz-Krzemien S
Hematol Oncol; 2017 Jun; 35(2):225-231. PubMed ID: 28620928
[TBL] [Abstract][Full Text] [Related]
49. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.
Avigan D; Hari P; Battiwalla M; Bishop MR; Giralt SA; Hardy NM; Kröger N; Wayne AS; Hsu KC
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1661-9. PubMed ID: 24018393
[TBL] [Abstract][Full Text] [Related]
50. Melphalan 140 mg/m
Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
[TBL] [Abstract][Full Text] [Related]
51. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
Nagler A; Or R; Naparstek E; Varadi G; Slavin S
Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
[TBL] [Abstract][Full Text] [Related]
52. Metachronous Second Primary Malignancies after Head and Neck Cancer in a Korean Cohort (1993-2010).
Jung YS; Lim J; Jung KW; Ryu J; Won YJ
PLoS One; 2015; 10(7):e0134160. PubMed ID: 26218068
[TBL] [Abstract][Full Text] [Related]
53. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
54. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma.
Lee DH; Roh JL; Baek S; Jung JH; Choi SH; Nam SY; Kim SY
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):579-86. PubMed ID: 23820107
[TBL] [Abstract][Full Text] [Related]
55. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
[TBL] [Abstract][Full Text] [Related]
56. Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy.
Ozdemir Y; Topkan E
Indian J Cancer; 2019; 56(1):29-34. PubMed ID: 30950440
[TBL] [Abstract][Full Text] [Related]
57. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
59. Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.
Kasarełło K; Snarski E; Sulejczak D; Ciesielski T; Wiśniewska A; Wrzesień R; Cudnoch-Jędrzejewska A
Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):17. PubMed ID: 34181099
[TBL] [Abstract][Full Text] [Related]
60. [Second primary malignancies among patients with myeloma-related-diseases in the KMF database].
Kosugi S; Shibayama H; Nakatani E; Kida T; Ohta K; Kaneko H; Yagi H; Tanaka H; Fuchida S; Nakaya A; Kobayashi M; Kuroda J; Kamitsuji Y; Uoshima N; Adachi Y; Tsudo M; Shimazaki C; Nomura S; Hino M; Matsumura I; Taniwaki M; Kanakura Y; Takaori-Kondo A
Rinsho Ketsueki; 2016 Jul; 57(7):839-47. PubMed ID: 27498726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
